Analyst Price Targets — LAB
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| April 4, 2024 2:41 am | Matthew Stanton | Jefferies | $3.25 | $2.66 | StreetInsider | Jefferies Starts Standard BioTools Inc (LAB) at Buy, 'Platform Building & Setting a New Standard' |
Latest News for LAB
BOSTON, Mass. , Aug. 05, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (the "Company" or "Standard BioTools") today announced financial results for the quarter ended June 30, 2026. Recent Highlights: Second quarter 2026 revenue of $20.
BOSTON, Mass., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (the “Company” or “Standard BioTools”) today announced financial results for the quarter ended June 30, 2026.
Sale of Mass Cytometry Business to Multiplex Bio Ensures Full Continuity of CyTOF and Hyperion Product Lines, Customer Relationships, Dedicated Team and Continued Investment in Next Generation Multiplex Platforms
BOSTON, Mass., July 22, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced that it will publish its second quarter 2026 financial results on Wednesday, August 5, 2026, after U.S. market close. About Standard BioTools Inc.
Are DXLG, LAB, FHB, RLYB Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, July 21, 2026
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for LAB.
U.S. House Trading
No House trades found for LAB.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.